anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
There has been a major growth in global health networks in recent decades to address health issues including tobacco use, alcohol abuse, and maternal mortality. Most conditions that incur high costs have provoked networks of advocates working to mitigate the impact, increase investment in research, and establish campaigns. Global health networks often work simultaneously across policy, knowledge creation, and advocacy. Until recently there has been limited activity in global health networks and advocacy addressing hearing loss and deafness which has contributed to its relatively low visibility with policymakers compared to other health conditions. This discussion paper reports on a global consultation that explored the views of advocacy groups and individuals on advocacy for the management of hearing loss, and cochlear implantation (CI). It focussed on stakeholders' views of current advocacy endeavours, opportunities and barriers, and the possible development of a global advocacy network to improve access to cochlear implantation and the supporting services. The subsequent development of a global health network, the Cochlear Implant International Community of Action (CIICA) is discussed and the conditions necessary for the successful development of health networks are explored. This paper will be of interest to those wishing to understand the factors influencing the development of health networks and advocacy.
Although doxepin HCl does have H1 and H2 histamine receptor blocking actions, the exact mechanism by which doxepin exerts its antipruritic effect is unknown. Doxepin Hydrochloride Cream, 5% can produce drowsiness which may reduce awareness, including awareness of pruritic symptoms. In 19 pruritic eczema patients treated with Doxepin Hydrochloride Cream, 5%, plasma doxepin concentrations ranged from nondetectable to 47 ng/mL from percutaneous absorption. Plasma levels from topical application of Doxepin Hydrochloride Cream, 5% can result in CNS and other systemic side effects.

Once absorbed into the systemic circulation, doxepin undergoes hepatic metabolism that results in conversion to pharmacologically-active desmethyldoxepin. Further glucuronidation results in urinary excretion of the parent drug and its metabolites. Desmethyldoxepin has a half-life that ranges from 28 to 52 hours and is not affected by multiple dosing. Plasma levels of both doxepin and desmethyldoxepin are highly variable and are poorly correlated with dosage. Wide distribution occurs in body tissues including lungs, heart, brain, and liver. Renal disease, genetic factors, age, and other medications affect the metabolism and subsequent elimination of doxepin. (See PRECAUTIONS - Drug Interactions.)
A composition for producing a biocide is provided. The composition comprises an ammonium salt, aqueous ammonia and sodium bicarbonate. The composition can be mixed with a hypochlorite oxidant to form a biocide. Previously known compositions included only an ammonium salt and optionally a base. The present composition is more economically favorable and has a more optimum pH relative to previously known compositions comprising an ammonium salt of a strong acid (hydrobromic, hydrochloric or sulfuric) or comprising ammonium carbamate and sodium hydroxide. Preparation of the biocide can be monitored with a control parameter. A new control parameter, the ratio ORP/pH, is introduced.
NEW MATERIAL:The peptide of formula [A is Gly or Ala; B is Phe or alkyl- Phe; D is Met, Met-sulfoxide or Leu; E is Ser or Tyr; F is Gly or Glu; G is Ala or Val; Y is OH or NR<1>R<2> (R<1> and R<2> are H or alkyl); the steric configuration of the amino acid residues is D, L or DL]. USE:An analgesic agent. PROCESS:The objective peptide can be prepared using either liquid-phase or solid- phase peptide synthesis process, by protecting the amino groups and carboxyl groups having no participation in the reaction, extending the N-terminal of the starting raw material successively with required peptide chains by the synthesis process such as mixed acid anhydride process, axide process, etc. until the last peptide chain is bonded to the chain, and removing the protecting groups by conventional process (e.g. treatment with trifluoroacetic acid, reduction, etc.).
PURPOSE:To obtain the subject foaming composition having an excellent cooling effect without giving a bitter taste to the tongue or causing a bur in the throat by using a specified ratio of a foaming agent capable of generating CO2 when dissolved in the mouth, an endothermic substance and 1-menthol included in or adsorbed on a degradated starch in combination. CONSTITUTION:This solid dental foaming composition is composed of 0.5 to 40wt.% foaming agent capable of foaming C02 when dissolved in the mouth, 50 to 98wt.% adsorbent capable of allowing in endothermic reaction to take place when dissolved in the mouth and 1-menthol included in or adsorbed on a degradated starch in which the amount of 1-menthol is 0.02 to 20wt.% based on the composition, capable of acting on the coating of tongue and the periglottis and giving a cool feeling to the inside of the mouth and useful in the fields of quasidrug, cosmetic, food, etc. As the foaming agent, e.g. a combination of a carbonate (e.g. potassium bicarbonate) and an organic acid (e.g. malic acid) is preferably used. As the endothermic substance, e.g. a crystalline xylylate is preferably used. As the 1-menthol component, a natural essential oil such as peppermint oil included in or adsorbed on a degradated starch such as porous dextrin is used.
Group C was not administered any medication during the study period lasting two months. Following this period, the clinical periodontal parameters were evaluated once again. Moreover, to analyze the total antioxidant capacity in saliva before and after the consumption of these supplements, as well as in individuals who were not given any medication, 2 ml of non-stimulated saliva was gathered from every participant at the commencement and conclusion of the study. This analysis was conducted using UV-spectrophotometric techniques.
The present invention discloses a bee pupa tablet which adopts bee pupas as main raw materials and is convenient for being taken, and a processing technology thereof. The bee pupa tablet is prepared by processing the components of the following formula (metered by weight): 40 to 60 parts of dry bee pupa, 0 to 30 parts of aloe dry leaf, 20 to 30 parts of propolis and 5 to 10 parts of starch. The processing technology comprises the steps of raw material selection and preparation, granulation, tablet press, test and package. The present invention is characterized in that the raw materials are formed by that the dry bee pupa and the aloe dry leaf are pulverized and are sieved by a sieve of 40 to 80 meshes, the mixed powder is stirred and evenly mixed with the starch to obtain the fine powder of the raw materials, the obtained granules are formed by mixing the fine powder of the raw materials and the propolis liquid, and the granules are dried and are sieved by a sieve of 24 meshes. The tablet of the present invention is convenient to be taken and can strengthening a human body and prolonging life for adding the aloe. The tablet has a good adjuvant treatment function for immunity increase and the restoration of a person who carries out radiotherapy and chemotherapy. The present invention has the advantages of simple processing technology and convenient and easy production.
Minor wounds will be created on participant's forearms (four per arm) by a certified laser specialist. On the randomized wound site, hydrocolloid pad will be applied. This treatment will be changed daily from Day 1 through Day 6 and all wound sites will be uncovered from Day 7 to Day 16 for assessments.
The safety and effectiveness of FIORICET with CODEINE in pediatric patients have not been established.

Life-threatening respiratory depression and deaths have occurred in children who received codeine [see Warnings and Precautions (5.5)]. In most of the reported cases, these events followed tonsillectomy and/or adenoidectomy, and many of the children had evidence of being ultra-rapid metabolizers of codeine (i.e., multiple copies of the gene for cytochrome P450 isoenzyme 2D6 or high morphine concentrations). Children with sleep apnea may be particularly sensitive to the respiratory depressant effects of codeine. Because of the risk of life-threatening respiratory depression and death:

  * FIORICET with CODEINE is contraindicated for all children younger than 12 years of age [see Contraindications (4)].

  * FIORICET with CODEINE is contraindicated for post-operative management in pediatric patients younger than 18 years of age following tonsillectomy and/or adenoidectomy [see Contraindications (4)].

  * Avoid the use of FIORICET with CODEINE in adolescents 12 to 18 years of age who have other risk factors that may increase their sensitivity to the respiratory depressant effects of codeine unless the benefits outweigh the risks. Risk factors include conditions associated with hypoventilation, such as post-operative status, obstructive sleep apnea, obesity, severe pulmonary disease, neuromuscular disease, and concomitant use of other medications that cause respiratory depression [see Warnings and Precautions (5.5)].
Baseline FACBC PET/PEM will be scheduled within 1 week of beginning neoadjuvant therapy. A repeat FACBC PET/PEM will be scheduled after the conclusion of neoadjuvant therapy, and before definitive surgical management.
Adalimumab 40 mg SC at Weeks 0, 2, and every 2 weeks through Week 52. At Week 16, subjects who have \< 20% improvement from baseline in both swollen and tender joint counts will early escape in a blinded fashion and receive adalimumab 40 mg every week through Week 52.
Molecular hydrogen is an emerging broad-spectrum antioxidant molecule that can be used to treat myocardial infarction (MI). However, with hydrogen inhalation, the concentration that can be reached within target organs is low and the duration of action is short, which makes it difficult to achieve high dose targeted delivery of hydrogen to the heart, seriously limiting the therapeutic potential of hydrogen for MI. As a result of reactions with the internal environment of the body, subcutaneous implantation of magnesium slices leads to continuous endogenous hydrogen production, leading to a higher hydrogen concentration and a longer duration of action in target organs. In this study, we propose magnesium implant-based hydrogen therapy for MI. After subcutaneous implantation of magnesium slices in the dorsum of rats, we measured hydrogen production and efficiency, and evaluated the safety of this approach. Compared with hydrogen inhalation, it significantly improved cardiac function in rats with MI. Magnesium implantation also cleared free radicals that were released as a result of mitochondrial dysfunction, as well as suppressing cardiomyocyte apoptosis.
PURPOSE:To obtain a drug for animal having extremely high stability in feed or drinking water and exhibiting activity of ascorbic acid, by using L-ascorbic acid 2-phosphoric acid ester or its salt as an active component. CONSTITUTION:A drug for animal is produced by using L-ascorbic acid 2-phosphoric acid ester or its salt (e.g. Na salt, K salt, Ca salt, Mg salt, etc.) as an active component. Sufficient effect can be attained by administering 0.01-0.5m-mol of the above active component per 1kg of feed or 1l of drinking water for preventing the breakage of eggshell and improving the egg quality of poultry or 0.003-0.03m-mol of the active component daily per 1kg of the body weight of poultry for anti-cholesterol agent or health drug for animal. It is administered by compounding the active component to talc, surfactant, etc., and adding the drug composition to a feed or drinking water or injecting the composition to an animal.
The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs such as linezolid and intravenous methylene blue), or with antipsychotics or other dopamine antagonists.

Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular changes (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for emergence of serotonin syndrome.

The concomitant use of buspirone with MAOIs intended to treat depression is contraindicated. Buspirone should also not be started in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue. All reports with methylene blue that provided information on the route of administration involved intravenous administration in the dose range of 1 mg/kg to 8 mg/kg. There have been no reports involving the administration of methylene blue by other routes (such as oral tablets or local tissue injection) or at lower doses. There may be circumstances when it is necessary to initiate treatment with a reversible MAOI such as linezolid or intravenous methylene blue in a patient taking buspirone. Buspirone should be discontinued before initiating treatment with the reversible MAOI [see CONTRAINDICATIONS,DOSAGE AND ADMINISTRATION AND DRUG INTERACTIONS].

If concomitant use of buspirone with a 5-hydroxytryptmine receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.

The concomitant use of buspirone with serotonin precursors (such as tryptophan) is not recommended.

Treatment with buspirone and any concomitant serotonergic or antidopaminergic agents, including antipsychotics, should be discontinued immediately if the above events occur and supportive symptomatic treatment should be initiated.

Because buspirone hydrochloride tablets have no established antipsychotic activity, it should not be employed in lieu of appropriate antipsychotic treatment.
BACKGROUND: The Modified Fels (mFels) and Abbreviated Modified Fels (abFels) knee systems have been recently developed as options for grading skeletal maturity without the need for a separate hand radiograph. We sought to determine the interobserver reliability of these systems and to compare their prediction accuracy with that of the Greulich and Pyle (G-P) atlas in a cohort managed with epiphysiodesis for leg-length discrepancy (LLD).
METHODS: Three reviewers scored 20 knee radiographs using the mFels system, which includes 5 qualitative and 2 quantitative measures as well as a quantitative output. Short leg length (SL), long leg length (LL), and LLD prediction errors at maturity using the White-Menelaus (W-M) method and G-P, mFels, or abFels skeletal age were compared in a cohort of 60 patients managed with epiphysiodesis for LLD.
RESULTS: Intraclass correlation coefficients for the 2 quantitative variables and the quantitative output of the mFels system using 20 knee radiographs ranged from 0.55 to 0.98, and kappa coefficients for the 5 qualitative variables ranged from 0.56 to 1, indicating a reliability range from moderate to excellent. In the epiphysiodesis cohort, G-P skeletal age was on average 0.25 year older than mFels and abFels skeletal ages, most notably in females. The majority of average prediction errors between G-P, mFels, and abFels were <0.5 cm, with the greatest error being for the SL prediction in females, which approached 1 cm. Skeletal-age estimates with the mFels and abFels systems were statistically comparable.
CONCLUSIONS: The mFels skeletal-age system is a reproducible method of determining skeletal age. Prediction errors in mFels and abFels skeletal ages were clinically comparable with those in G-P skeletal ages in this epiphysiodesis cohort. Further work is warranted to optimize and validate the accuracy of mFels and abFels skeletal ages to predict LLD and the impact of epiphysiodesis, particularly in females. Both the mFels and abFels systems are promising means of estimating skeletal age, avoiding additional radiation and health-care expenditure.
LEVEL OF EVIDENCE: Prognostic Level II . See Instructions for Authors for a complete description of levels of evidence.
Participants who received standard rehabilitation program after surgery. The control group, before performing the functional exercises watched two videos of different landscapes lasting 4 minutes each.
A Randomized control trial of 6 month period was done. Patients with luxation injuries aged between 16- 50 years were asked to participate in the study after taking informed consent. They were then assigned to either group (Group 1: Packable Composite (PC), Group 2: Bulkfill Flowable) by lottery method. Periotest was used to check the mobility of teeth before the placement of splint. Splinting was performed with composite material according to group allocation. Time taken to place the splint was recorded. Frontal view images of splinted teeth were taken with DSLR and transferred to Adobe Photoshop Version 22.4.1 for windows to measure surface area of the restorative material in percentage to total tooth surface area. Post-operative instructions were given. After 2 weeks, Periotest readings were recorded, immediately after removal of splint. On both visits 3 readings per tooth were recorded. Time taken to remove the splint was also recorded. Additionally, the retention of splint was also observed.

STATISTICAL ANALYSIS:

SPSS version 26 for windows was used, the mean time taken to apply and remove the material and mobility before and after removal of splint was compared using the independent samples T test. Mann-Whitney test compared the percentage area of the material occupied. Fisher's Eaxct test evaluated the retention of splint material. Level of significance was kept at p ≤0.05.
FIELD: medicine, dermatology. SUBSTANCE: method involves parenteral use of preparation of α 2 - and γ-interferons made by genetic engineering methods. Preparations of a 2 - and γ-interferons made by genetic engineering methods are administrated to patients intradermally or subcutaneously or intramuscularly every day or every other day for 3-20 days. Preparations of a 2 - and γ-interferons are administrated simultaneously at their ratio 10:1 at a single dose from 500000 to 2500000 IU and from 50000 to 250000 IU, respectively, initially at maximal dose without side reactions. Dose is changed depending on the individual tolerance, clinical dynamics of disease and in combination with known methods of treatment (for example, antibiotics, local anesthetics). EFFECT: shortened time of treatment by 1.2-1.5 times. 2 cl
Chronic kidney disease is a significant cause of morbidity and mortality worldwide. In recent years, Galectin-3 has been put forward as a potential biomarker of chronic kidney disease progression. This review aims to assess the clinical utility of Galectin-3 in various pathological processes leading up to chronic kidney disease such as diabetes and lupus nephritis. We conducted a systematic search on PubMed from inception to September 2023, using the search term ("Galectin-3" OR "gal-3") AND ("renal" OR "kidney"). Galectin-3 has been shown to be both pro-fibrotic and protective against renal fibrosis through various mechanisms such as apoptotic body clearance and modulation of the Wnt pathway. Studies have found associations between raised Galectin-3, incidence and progression of chronic kidney disease. In lupus nephritis, Galectin-3 may serve as a biomarker for lupus nephritis activity. Although Galectin-3 inhibits cystogenesis, there is no correlation between total kidney volume and Galectin-3 in polycystic kidney disease. The role of Galectin-3 in staging and prognostication of renal cell carcinoma is yet to be determined. Galectin-3 has potential in predicting chronic kidney disease progression, in combination with other biomarkers. However, more trials are required given that present studies demonstrate conflicting results on the relationship between Galectin-3 and clinical outcomes in chronic kidney disease patients of varying aetiologies.
The objective of this observational program is to evaluate the efficacy and safety of the gonadotropins used for COS in ART. The clinical use of the various progesterone preparations will also be monitored and registered. All medications will be used according to normal clinical practice, as described in the Summary of Product Characteristics (SmPC). From the start of the program cycles data will be collected prospectively for 12 months and also a substantial amount of cycles will be analyzed retrospectively for the previous 6 months. Data will be collected from all subjects stimulated by follicle stimulating hormone (FSH), with or without down regulation and exogenous lutenizing hormone (LH) supplementation, and final follicular maturation triggered by human chorionic gonadotropin (hCG) and luteal phase support by any means for COS in ART and intracytosolic sperm injection (ICSI). All the medications should be used according to usual clinical practice. Data related to pretreatment (basal examination, history of infertility, LH suppression), stimulation (gonadotropin use, concomitant medications, luteal phase supplementation, ovulation triggering, cycle cancellation, fertilization methods), safety aspects and clinical outcome will be captured.
81794975 ABSTRACT Provided herein is an aqueous composition comprising low levels of aluminum-containing salts stabilized by disodium EDTA. When disodium EDTA is substituted for tetrasodium EDTA, the reduction in stability of the aluminum-containing salt, and the shift from the active Peak 4 species to the less active Peak 3 species is inhibited. The aluminum salt is present in an amount of 0.2 weight % to 3 weight % by total weight of the composition on an anhydrous basis. The disodium EDTA is present in the composition in an amount of 0.1 weight % to 0.4 weight % by total weight of the composition. The pH of the composition is from 2 to 5. The composition may be used as an antiperspirant when applied to the axillary area of a person. Date Recue/Date Received 2020-08-11
Lung adenocarcinoma (LUAD) is the leading cause of cancer-related death worldwide, but the underlying molecular mechanisms remain largely unclear. The transcription factor (TF) specificity protein 1 (SP1) plays a crucial role in the development of various cancers, including LUAD. Recent studies have indicated that master TFs may form phase-separated macromolecular condensates to promote super-enhancer (SE) assembly and oncogene expression. In this study, we demonstrated that SP1 undergoes phase separation and that its zinc finger 3 in the DNA-binding domain is essential for this process. Through Cleavage Under Targets & Release Using Nuclease (CUT&RUN) using antibodies against SP1 and H3K27ac, we found a significant correlation between SP1 enrichment and SE elements, identified the regulator of the G protein signaling 20 (RGS20) gene as the most likely target regulated by SP1 through SE mechanisms, and verified this finding using different approaches. The oncogenic activity of SP1 relies on its phase separation ability and RGS20 gene activation, which can be abolished by glycogen synthase kinase J4 (GSK-J4), a demethylase inhibitor. Together, our findings provide evidence that SP1 regulates its target oncogene expression through phase separation and SE mechanisms, thereby promoting LUAD cell progression. This study also revealed an innovative target for LUAD therapies through intervening in SP1-mediated SE formation.